CSU IBC Meeting- APPROVED MINUTES

Meeting title	CSU IBC Meeting March 2026
Date	March 11, 2026
Convened at	8:32am
Location	TMI Rm 222
Open or closed meeting (If closed, why?)	The meeting was open for the entire time.
Review of prior meeting minutes	February 11, 2026 meeting minutes were approved as written.
Adjournment	9:00am
Recorded by	C. Johnson

Attendees

Check if Attending (Members):	**Check if Attending (Alternate Members):**
☒ Jessica Ayers, Animal expert	☐ Lon Kendall, Director LAR
☒ Donald Bade, Unaffiliated	
☒ Angela Bosco-Lauth, Associate Chair	
☒ Chaoping Chen, Chair	
☐ Jason Cummings, lab representative	
☐ Dan Frazen, Unaffiliated	
☒ Brendan Podell, Mycobacteria specialist	
☐ Ann Powers, Virology	
☒ Robyn Roberts, Plant expert	
☐ Joanie Ryan, Assistant Biosafety Director	☐ Rebecca Moritz, Biosafety Office Director*
☐ Tony Schountz, Virology	☒ Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 6 voting members; _6_ in attendance	*non-voting at this meeting
Non-Voting Members:	
☐	
☐ Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
☐ Michelle Ramey, Assistant Compliance Coord.	☒ Sonia Aleman Rivera, Assistant Biosafety Officer
☐ Nicole Marlenee, Biosecurity Specialist	☐ Kelly Kim, Assistant Biosafety Officer
☒ Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Mario Arango, OGC	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. **Review of February 11, 2026, IBC meeting minutes**
   The minutes were unanimously approved as written.

2. **Agent/Project Review**

a. PI name/Lab	**Easley Lab**
Project Number and Title	**26-011B: ARPA-H Washington University - Porcine NITRO Dosing Study**
Project Overview	This project involves an injectable "Smart Cell" Gene therapy to deliver gene circuits into endogenous cells of the joint. These gene circuits are minicircles that contain the minimal cassette of the desired therapeutic gene driven by an environmental responsive promoter. The therapeutic approaches involve needle-based delivery of a peptide-mediated nanocomplex into the joint space for long-term anti-inflammatory and regenerative, pain-modulating responses.
Planned Modifications	Gene circuits will be constructed to express therapeutic genes and injected into the joints, using a porcine OA model.
Pathogen/Viral Vector Forms	• NA
NIH Guidelines Section	III-D-4; III-E
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	1. Please describe how biohazardous waste will be treated (PPE and minipigs). 2. Please list what disinfectants will be used for surfaces, including concentration and contact time. 3. Will there be any biological sampling, necropsy, etc., as part of this study? If so, where and at what containment level will that occur? 4. Eye protection should be worn at all times in the lab and should be added to the protocol. 5. Is the PPE the same for all parts of the work, including for animal care staff? 6. Please describe how pigs need to be housed and how animal waste should be handled. 7. Please clarify where the animals treated will be housed and if other animals in same room are a concern.
Verification of training	All training is up to date.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project with modifications described above (see Discussion).
Vote	The motion was unanimously approved.
b. PI name/Lab	**Leach (Jan) Lab**
Project Number and Title	**26-012B: Identification of traits in Bacillus subtilis for survival in the air**

Project Overview	This project involves screening a recombinant Bacillus subtilis library for variants in aerobiome suvival traits developed by a collaborator. Once the variants are identified, mGWAS will be used to map the genetic regions and evaluate the contributions of those genes for the survival trait.
Planned Modifications	Genetic variants of Bacillus will be developed a collaborator
Agents used	• Bacillus subtilis
NIH Guidelines Section	III-E
Proposed containment conditions (BSL, ABSL, etc.)	BSL1
Discussion	Please describe PPE and disposal methods, be sure to include disinfectants (and their concentrations) that will be used for non-autoclavable items and surfaces.
Verification of training	All training is up to date.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project with modifications described above (see Discussion).
Vote	The motion was unanimously approved.
c. PI name/Lab	**MacNeill Lab**
Project Number and Title	**26-010B: Evaluation of an oncolytic virus (MYXVorfC) adjunct therapy to prevent recurrence of canine soft tissue sarcomas**
Project Overview	The goal of this project is to determine if recombinant oncolytic poxvirus therapy can reduce regrowth of tumors in dogs following surgery to remove spontaneously arising soft tissue sarcoma. The poxvirus being used is myxoma virus expressing orfC (MYXVorfC). Intratumoral MYXVorfC injections are safe and efficacious in murine cancer models. The safety of a similar recombinant MYXV therapy has been demonstrated in dogs with spontaneous soft tissue sarcoma.
Planned Modifications	Myxoma virus expressing orfC (MYXVorfC) will be injected intralesionally following tumor removal
Agents used	• attenuated recombinant myxoma virus
NIH Guidelines Section	III-D-1; III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	For the project: 1. The Risk Assessment describes bandaging of injection site after injection, however the PARF does not. Please clarify. 2. Likewise, the risk assessment mentions viral testing of samples to check for shedding, however this doesn't appear to be part of the current study. Please clarify. 3. Please add a statement to the Project Overview indicating that the study conforms to all the criteria outlined by the FDA Release of Client-Owned Animals When Conducting a Study to Develop Human Therapeutics Using Recombinant or Synthetic Nucleic Acid Molecules document.

	4. Please correct the NetID spelling for investigators.
Verification of training	Although it is not required for this project, one individual needs to complete the shipping training.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the project with modifications described above (see Discussion).
Vote	The motion was unanimously approved.

3. Amendments requiring full IBC review

d. PI name/Lab	**Schountz Lab**
Project Number and Title	**22-061B: BANAL CoV susceptibility of Jamaican fruit bats and deer mice**
Project Overview	This project will determine if Jamaican fruit bats and deer mice are susceptible to BANAL-236 or BANAL-52 CoV.
Planned Modifications	The two viruses have been made by a collaborator using infectious clone technology
Agents used	• BANAL-236 coronavirus
NIH Guidelines Section	III-D-1; III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Amendment request	Requesting to add Pfizer mRNA vaccine
Discussion	It is implied how the vaccine will be used but not fully described. The committee requested the following information regarding the vaccine use. 1. Which Pfizer mRNA vaccines will be used and in what species? 2. How will the vaccine be used/what is the intent? 3. What PPE and decontamination procedures will be used?
Verification of training	All training is up to date.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to table the amendment until the items described above are addressed (see Discussion), and to re-review the project by email.
Vote	The motion was unanimously approved.
e. PI name/Lab	**Medford Lab**
Project Number and Title	**20-065B: Functional Engineering of a Photosynthetic Desalination Flow Circuit**
Project Overview	This project is part of an ongoing effort to develop plants to provide Synthetic Desalination of seawater. Water pump gene parts were synthesized from natural components found in plants, and transgenic plants are generated using standard plant transformation vectors.
Planned Modifications	Generate transgenic plants using standard plant transformation vectors.
Agents used	• NA
NIH Guidelines Section	III-E-1

Proposed containment conditions (BSL, ABSL, etc.)	BSL1/BL1-P
Amendment request	add generation of transgenic kale and lettuce
Discussion	The project is currently approved for making transgenic Arabidopsis, watermelon, and tomato. The amendment request is to add the generation of transgenic kale and lettuce. This is a well-established lab using standard plant techniques. No concerns were noted.
Verification of training	All training is up to date.
Verification of facilities	The Lab is up to date on inspections.
Motion	A motion was made to approve the amendment request with no additional modification.
Vote	The motion was unanimously approved.

4. **New Business**
   None

5. **Unfinished Business**
   a. **NIH Initiative to Modernize and Strengthen Biosafety Oversight –** no updates (https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy#tab2/)

6. **Closed Session**
   a. No items to discuss

7. **Reports**

a. Coordinator's Report	1. Next IBC meeting: Wednesday, April 8, 2026
b. Biosafety Office Report	1. Inspections update: The Federal Select Agent Program will be conducting a remote document inspection April 13-16th. We believe they will be conducting an unannounced in-person inspection to see our facilities sometime after that. This is the new annual cadence for highly complex entities. 2. ORCC went to CSU Pueblo last week to tour some of the facilities and meet with the faculty. We are working with the staff and faculty there to get their research projects into SciShield. Once we have better view of the biological research, we can determine how best to proceed with overseeing it. 3. Incident Reports: There were no incidents this month involving rDNA.

8. **Public Comment**
   A member of the public asked when we were going to go back to online IBC meetings. The response was that the committee has decided to hold the meetings in person for the foreseeable future.

9. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	**a. Podell Lab** **Project:** Vaccine efficacy in the guinea pig model of tuberculosis (26-009B); BSL3/ABSL3; NIH Guidelines category non-exempt rDNA: III-D-4